Disseminating scientific findings internally and externally is an important concern of the SFB LIPID HYDROLYSIS. The scope for the different target groups ranges from guest lectures to symposia and press releases.
Our goal is to attract external researchers to present recent results to strengthen knowledge exchange within the international scientific community. The Guest Speaker Series was launched in Fall 2019 to facilitate and encourage external collaborations and provide opportunities for scientific interaction for PIs, team members, and students.
The next SFB Lipid Hydrolysis Retreat will take place from September 30 - October 2, 2024.
Anyone suffering from a rare metabolic disease needs an almost unaffordable treatment. A solution is being sought at the Medical University of Graz.
A deficiency of the fat-splitting enzyme lysosomal acid lipase (LAL) can cause liver inflammation (hepatitis). Med Uni Graz researchers have tested an active substance that could improve enzyme replacement therapy. It is a binding molecule for an intracellular receptor protein that shows potential to “improve metabolism and inflammatory processes in the liver that are involved in the development of liver inflammation”, according to the Medical University.
The latest publication of Monika Oberer's CRC subproject describes the interaction of newly discovered amino acids that are responsible for CGI-58 stimulating the activity of ATGL.
Publication:
Unmasking Crucial Residues in Adipose Triglyceride Lipase for Co-Activation with Comparative Gene Identification-58
Natalia Kulminskaya, Carlos Francisco Rodriguez Gamez, Peter Hofer, Ines Kathrin Cerk, Noopur Dubey, Roland Viertlmayr, Theo Sagmeister, Tea Pavkov-Keller, Rudolf Zechner, Monika Oberer
Journal of Lipid Research, DOI: 10.1016/j.jlr.2023.100491
"Ärzte exklusiv Newsletter" of August 2023 informs about the SFB Lipid Hydrolysis.
In the June issue of UNIVERSUM INNERE MEDIZIN, Dagmar KRATKY and Michael TRAUNER, two project leaders of the CRC, report on the "Role of lipid hydrolysis in selected metabolic diseases".
